Home/Pipeline/PPARγ Program

PPARγ Program

Metabolic Disorders

DiscoveryActive

Key Facts

Indication

Metabolic Disorders

Phase

Discovery

Status

Active

Company

Micar Innovation

About Micar Innovation

Micar Innovation is a private, pre-revenue biotech company providing AI-powered computational drug discovery services and developing its own internal pipeline. Its core technology platform integrates advanced molecular modeling, dynamics, and free energy calculations to de-risk and accelerate early-stage drug discovery, claiming to reduce the timeline for entire discovery processes to 2-8 weeks. The company targets orphan GPCRs, understudied proteins, and rare diseases, and has demonstrated its capabilities through published research on SARS-CoV-2 variants and partnerships for medicinal cosmetics development.

View full company profile

Therapeutic Areas

Rare Diseases Metabolic Disorders Oncology Neurological Disorders Infectious Diseases Cardiovascular

Other Metabolic Disorders Drugs

Drug	Company	Phase	Status
Novel GLP-1 Receptor Agonist	lupin	Pre-clinical/Clinical	Licensed (Gan & Lee)
Undisclosed Metabolic Program	Kallyope	Discovery	Active
Metabolic Disorders Program	Seragon Biosciences	Pre-clinical	Active
Pancreas-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-001	InVirtuoLabs	Discovery	Active
AmorphOX GLP-1	Orexo	Preclinical	Active
Amylin Program	Orion Biotechnology	Discovery	Active
Not specifically disclosed on public website	Taisho Pharmaceutical	Various	Active
TLC590	Taiwan Liposome Company	Phase 2	Active